SAN DIEGO, Aug. 23 /PRNewswire/ -- eBioscience Corporation announced the appointment of Todd R. Nelson, Ph.D., to CEO of eBioscience, effective immediately. Dr. Nelson comes to eBioscience from Invitrogen Corporation where he was Vice President, Global Corporate Development.
Dr. Nelson will assume the role of CEO and Lily Lai, eBioscience's founder, will remain as President during a transition period. Nelson will also join eBioscience's Board of Directors.
Dr. Nelson commented: "I'm very excited about joining a fast growing company with the reputation and potential of eBioscience. The company's breakthrough products and enabling technologies are critical to the future of biotechnology and life science research."
Dr. Brian Seed, the Lead Director on eBioscience's Board of Directors, commented: "Todd has exceptional technical, financial and operating experience, and the energy and strategic vision to lead eBioscience through its next stage of growth."
Seed continued: "During Lily's tenure as President, eBioscience has grown from a start-up enterprise to a fast growing, profitable company that now has more than 1,000 products on the market, and a strong brand within the life science research community. We are grateful for her many contributions to eBioscience."
Todd R. Nelson was named Vice President Global Corporate Development and Strategy of Invitrogen Corporation in 2005. In addition to being responsible for mergers and acquisitions functions globally, Nelson held primary responsibility for the development and implementation of both corporate and divisional strategies for the organization on a world wide basis. Prior to that, he was Managing Director and Head, Global Life Sciences Corporate Strategy and Research at RBC Capital Markets, and First Vice President, Global Corporate Strategy and Economics at Merrill Lynch in New York.
Dr. Nelson has been a visible figure within the Life Sciences industry.
During his more than 1
|SOURCE eBioscience, Inc.|
Copyright©2007 PR Newswire.
All rights reserved